Thanks for passing this on, I heard about this through the Lyme Disease support group about a year ago. I would never take the vaccine personally from things I have heard. Susan L
<< > SmithKline (SBH) Sued Over Lyme Vaccine > > WEST CHESTER, Pa., Dec. 14 /PRNewswire/ -- A class action lawsuit > filed > today in > Pennsylvania claims the vaccine that prevents Lyme Disease causes an > incurable form of > autoimmune arthritis and, for some, could produce symptoms far worse > than > those brought on by > the illness. ``Mealey's Litigation Report: Drug and Medical Devices'' > informed subscribers about > the complaint today. > > The complaint, filed in Chester County Court of Common Pleas, alleges > SmithKline Beecham > (NYSE: SBH - news), manufacturers of the widely touted LYMErix > vaccine, > failed to warn > doctors and the general public that nearly 30 percent of the > population was > pre-disposed to a > degenerative autoimmune syndrome, which the lawsuit says is triggered > by > contents of the > inoculation. > > ``Once this autoimmune reaction is triggered, it cannot be cured and > can > only be treated > symptomatically for the remainder of the vaccine recipient's life,'' > the > complaint says. > > According to the class action, SmithKline (SBH) used high > concentrations of > a surface protein > called OspA as the foundation for its vaccine. When bitten by a Lyme > infected parasite, humans > are not exposed to OspA protein. The levels of OspA that enter the > bloodstream at any phase of > the three-dose LYMErix vaccine, however, place patients classified by > genetic type HLA-DR4+ > at risk of developing a condition referred to as > ``treatment-resistant'' > Lyme Arthritis, the lawsuit > says. > > Despite this ``well documented relationship'' between OspA and > treatment-resistant Lyme > Arthritis, SmithKline neglected to include the information in its > widely > disseminated promotional > literature and insisted LYMErix was safe and generally well tolerated, > the > class action says. > > About one-third of the general population is HLA-DR4+ and risks > contracting > the arthritic > condition when exposed to the vaccine, according to the complaint. The > HLA-DR4+ trait is easily > detected by a routine blood test; however, SmithKline never > recommended that > doctors screen for > the trait before administering the vaccine, the lawsuit alleges. > > The complaint further alleges that patients who are infected with Lyme > bacteria when they > receive LYMErix -- whether asymptomatic or in the early stages of > infection -- could suffer > symptoms more progressive and enhanced than if they had not received > the > vaccine. > > SmithKline, the class action says, also neglected to inform doctors > and the > general public that > periodic booster shots beyond the series of three vaccinations would > be > necessary to maintain > immunity to the disease. > > The class action includes counts of negligence, unfair trade practices > and a > bid for medical > monitoring of those who are placed at risk of developing autoimmune > arthritis but have not yet > been diagnosed with the condition. > > The class action complaint was filed by Stephen A. Sheller and Albert > J. > Brooks Jr. of Sheller, > Ludwig & Badey in Philadelphia. > > Sheller said that in the wake of filing the class action, he expects > to file > claims on behalf of > individuals who received the LYMErix vaccine and are now suffering > from the > autoimmune > arthritis. > > For more information about Mealey Publications, log on to > www.mealeys.com or > call > 1-800-MEALEYS or 610-768-7800, or contact the Company via e-mail at > [email protected] . > > SOURCE: Mealey Publications >> -- The silver-list is a moderated forum for discussion of colloidal silver. To join or quit silver-list or silver-digest send an e-mail message to: [email protected] -or- [email protected] with the word subscribe or unsubscribe in the SUBJECT line. To post, address your message to: [email protected] Silver-list archive: http://escribe.com/health/thesilverlist/index.html List maintainer: Mike Devour <[email protected]>
